Citation :

Niharika Rao, "Stem Cell Transplantation For Leukemia Treatment: An Overview, Clinical Trials, and Stem Cell Donation," International Journal of Pharmacy and Biomedical Engineering, vol. 13, no. 1, pp. 1-8, 2026. Crossref, https://doi.org/10.14445/IJPBE-V13I1P101

Abstract

Leukemia is a heterogeneous cluster of hematological malignancies associated with the uncontrolled proliferation of abnormal blood-forming cells, resulting in systemic complications. Although there have been a lot of advances regarding the biological understanding of leukemia, treatment of the disease has been complicated by the heterogeneity of the disease and relapse. The existing treatment modalities have increased rates of remission and survival, as per research. Nevertheless, these treatment approaches frequently suffer drawbacks with drug resistance, toxicity, failure to eliminate all leukemic stem cells, and high relapse rates, especially in high-risk and refractory situations. Stem Cell Transplantation (SCT) is a novel therapeutic approach that has the ability to surmount some of the drawbacks of traditional therapies. The great benefit of SCT is that it results in the recovery of normal hematopoiesis after intense conditioning therapy. Autologous and allogeneic SCT are both useful in the treatment of leukemia and vary according to type, stage, and specifics of the patient. This review outlines the use of various sources of stem cells in the treatment of leukemia. Overall, SCT represents a critical and evolving component of leukemia treatment, supported by robust clinical evidence and ongoing research aimed at improving safety, accessibility, and outcomes.

Keywords

Biology, Cancer Biology, Leukemia, Stem Cells, Clinical Trials.

References

1. Adithya Chennamadhavuni et al., Leukemia, PubMed, 2026.
   [Publisher Link]
2. Indunil Karunarathna et al., Leukemia: Classification, Risk Factors, Management, Treatment and Diagnostic Challenges, ResearchGate, 2012.
   [CrossRef] [Publisher Link]
3. M.T. Amjad, A. Kasi, and A. Chidharla, Cancer Chemotherapy, PubMed, 2023.
   [Publisher Link]
4. Hany E. Marei, “Stem Cell Therapy: A Revolutionary Cure or a Pandora’s Box,” Stem Cell Research & Therapy, vol. 16, no. 1, pp. 1-24, 2025.
   [CrossRef] [Google Scholar] [Publisher Link]
5. Azizbek Mo‘minjonov Akmaljon o‘g‘li, Mamatojiyev Shohjahon Abdullajon o‘g‘li, and Musayev Hamid Alimardonovich, “Leukemia – Types, Clinical Appearances, Diagnosis And Treatment,” Web of Medicine: Journal of Medicine, Practice and Nursing, vol. 2, no. 4, pp. 10-17, 2024. [Google Scholar] [Publisher Link]
6. Amanda S. Davis, Anthony J. Viera, and Monica D. Mead, “Leukemia: An Overview for Primary Care,” American Family Physician, vol. 89, no. 9, pp. 731-738, 2014.
   [Google Scholar] [Publisher Link]
7. T. Terwilliger, and M. Abdul-Hay, “Acute Lymphoblastic Leukemia: A Comprehensive Review and 2017 Update,” Blood Cancer Journal, vol. 7, no. 6, pp. 1-12, 2017.
   [CrossRef] [Google Scholar] [Publisher Link]
8. Cameron K. Tebbi, “Etiology of Acute Leukemia: A Review,” Cancers, vol. 13, no. 9, pp. 1-19, 2021.
   [CrossRef] [Google Scholar] [Publisher Link]
9. M.W.  Jin et al., “A Review of Risk Factors for Childhood Leukemia,” European Review for Medical and Pharmacological Sciences, vol. 20, pp. 3760-3764, 2016.
   [Google Scholar] [Publisher Link]
10. Austin L. Brown et al., “Inherited Genetic Susceptibility to Acute Lymphoblastic Leukemia in down Syndrome,” Blood, vol. 134, no. 15, pp. 1227-1237, 2019.
    [CrossRef] [Google Scholar] [Publisher Link]
11. Bert Vogelstein et al., “Cancer Genome Landscapes,” Science, vol. 339, no. 6127, pp. 1546-1558, 2013.
    [CrossRef] [Google Scholar] [Publisher Link]
12. Marta Malczewska et al., “Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia,” Cancers, vol. 14, no. 8, pp. 1-20, 2021.
    [CrossRef] [Google Scholar] [Publisher Link]
13. National Cancer Institute, Adult Acute Myeloid Leukemia Treatment, National Cancer Institute. [Online]. Available:https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
14. National Cancer Institute. Chronic Myelogenous Leukemia Treatment. National Cancer Institute. [Online]. Available: https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq
15. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment. National Cancer Institute. [Online]. Available:https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq
16. Karam Khaddour, Caroline K. Hana, and Prerna Mewawalla, Hematopoietic Stem Cell Transplantation (Bone Marrow Transplant), PubMed, 2023.
    [Publisher Link]
17. Robert S. Negrin, “Graft-Versus-Host Disease versus Graft-Versus-Leukemia,” Hematology, vol. 2015, no. 1, pp. 225-230, 2015.
    [CrossRef] [Google Scholar] [Publisher Link]
18. Gashaw Dessie et al., “Role of Stem-Cell Transplantation in Leukemia Treatment,” Stem Cells and Cloning: Advances and Applications, vol. 13, pp. 67-77, 2020.
    [CrossRef] [Google Scholar] [Publisher Link]
19. Cheng-Hsien Wu et al., “Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia,” International Journal of Molecular Sciences, vol. 25, no. 5, pp. 2527-2527, 2024.
    [CrossRef] [Google Scholar] [Publisher Link]
20. Ezzatollah Fathi, Zohreh Sanaat, and Raheleh Farahzadi, “Mesenchymal Stem Cells in Acute Myeloid Leukemia: A Focus on Mechanisms Involved and Therapeutic Concepts,” Blood Research, vol. 54, no, 3, pp. 1-10, 2019.
    [CrossRef] [Google Scholar] [Publisher Link]
21. Hassan Nourmohammadi et al., “Gene-Edited Hematopoietic Stem Cells for Leukemia and Lymphoma Treatment: A Systematic Review of Preclinical and Translational Evidence,” Discover Oncology, vol. 16, no. 1, 2025.
    [CrossRef] [Google Scholar] [Publisher Link]
22. Leventhal et al., “The Benefits and Risks of Stem Cell Technology,” Oral Diseases, vol. 18, no. 3, pp. 217-222, 2011.
    [CrossRef] [Google Scholar] [Publisher Link]
23. Shu-Huey Chen, Tso-Fu Wang, and Kuo-Liang Yang, “Hematopoietic Stem Cell Donatio,” International Journal of Hematology, vol. 97, no. 4, pp. 446-455, 2013.
    [CrossRef] [Google Scholar] [Publisher Link]
24. Juliet N. Barker, and John E. Wagner, “Umbilical-Cord Blood Transplantation for the Treatment of Cancer,” Nature Reviews Cancer, vol. 3, no. 7, pp. 526-532, 2003.
    [CrossRef] [Google Scholar] [Publisher Link]